Novo Nordisk's insulin aspart franchise is a ... having a biosimilar option for their rapid-acting insulin injection can truly make a difference, as biosimilar products have the potential to ...

The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir but he had to do so because of market forces.

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

A U.S. federal court has approved a settlement between Novo Nordisk (NVO) and Minnesota ending a longstanding litigation that accused three leading insulin manufacturers of charging excessive ...

Pharmac will fund a new type of insulin for people with diabetes, branded as Ryzodeg, from May 1 2025. Pharmac’s Director ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

Two prefilled, disposable insulin pen devices were used: InnoLet and FlexPen (Novo Nordisk ... to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart ...

Pharmac will fund a new type of insulin for people with diabetes, branded as Ryzodeg, from 1 May 2025. Pharmac’s Director Pharmaceuticals, Geraldine MacGibbon, expects about 13,000 people with ...